MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation (NCT01380145), a na phase 1 study. The primary outcome is Assessment of Safety of recMAGE-A3 + AS15.

2. Clinical Question

The study’s primary objective was to assess the safety and tolerability of immunizations administered before stem cell mobilization and multiple times after stem cell reinfusion. The primary safety assessment covered treatment-emergent adverse events reported through clinical laboratory tests, physical examinations and vital signs. The registry describes severity grading according to NCI CTCAE, Version 4.0, and a monitoring period of up to 14 months.

The study also had secondary objectives: assessing MAGE-A3-specific humoral and cellular immune responses, tumor response, survival and time to subsequent therapy. These objectives are distinct from the primary safety question. The registry record describes them as objectives, but the available primary safety figures alone do not establish the findings for those other outcomes.

Because there was no comparator group, the study can describe events observed among participants who received the immunizations, but it cannot make a like-for-like estimate of how event rates differed from another treatment or from no study intervention. The registry record does not report a randomized comparison or a control arm.

3. Trial Design

This was a phase 1, open-label, single-group pilot study of recMAGE-A3 protein plus AS15 in people with multiple myeloma undergoing autologous stem cell transplantation. The registry reports enrollment of 13 participants. The study was not randomized, and there was no separate control group. The allocation and masking fields do not describe a randomized or blinded comparison.

Participants received a total of 8 immunizations, given before and after autologous stem cell transplantation. The stated primary objective was to determine safety and tolerability when immunizations were given before stem cell mobilization and multiple times after stem cell reinfusion. The registry describes safety monitoring as continuing for up to 14 months.

The enrolled population was defined by treatment history and transplant eligibility: participants had symptomatic multiple myeloma, had completed induction therapy with at least a Very Good Partial Response by International Myeloma Working Group criteria, and were eligible for high-dose chemotherapy with autologous stem cell transplantation. These criteria describe a specific clinical setting and should guide interpretation of how broadly the findings apply.

Secondary aims covered humoral and cellular immunogenicity, tumor response, survival and time to subsequent therapy. Their presence as objectives does not by itself establish that results were reported or that the study was designed to estimate treatment effects on those outcomes. The registry record reports 5 outcome measures and no analyses. Further details of the statistical plan, including any prespecified methods for secondary outcomes, are not reported in the registry record.

As a single-group pilot, the design is primarily descriptive for safety. Without a concurrent comparator, events observed during follow-up cannot be separated statistically into those associated with the immunization, the underlying disease, transplantation, other care or other causes. The design also does not support a randomized treatment-effect comparison.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The Safety Analysis Set comprises all subjects who received at least 1 immunization with study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Includes all subjects enrolled in the study.

6. Primary Endpoint

The registry lists the primary outcome as Assessment of Safety of recMAGE-A3 + AS15, measured over Continuously for up to 14 months.

The primary endpoint is an assessment of the safety of recMAGE-A3 plus AS15. The registry describes treatment-emergent adverse events reported from clinical laboratory tests, physical examinations and vital signs, with severity graded according to NCI CTCAE, Version 4.0. The stated monitoring period was continuously for up to 14 months.

Safety endpoints are used in early-phase studies to characterize what events occur during treatment and follow-up, and how severe those events are under the specified grading system. Counting participants with events gives a direct description of how many people in the analyzed group experienced an event; it is not the same as counting every event episode. The registry identifies the safety analysis population as participants who received at least 1 immunization.

The posted safety figures include 13 participants at risk for the serious-event grouping, with 4 affected, and 13 at risk for the other-event grouping, with 13 affected. These are descriptive counts in a small, single-group study. They do not, by themselves, quantify an excess or reduction relative to another treatment. Nor do they establish that an event was caused by the immunization: the registry record’s description of treatment-emergent events concerns when events were observed, not proof of causation.

The record does not report a confidence interval or a formal hypothesis test for the primary safety endpoint. The numbers therefore describe the observed safety experience, without a registry-reported inferential estimate of its precision.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation begins with the study design. This trial had one group and no randomized comparator. Therefore, its primary safety results are counts describing the participants who received study immunizations, not estimates of a difference between treatments. A comparison that is not part of the design cannot be recovered simply by applying a statistical test to the single-group counts.

What participant counts describe

A count of participants with an event answers a simple descriptive question: how many people in the defined safety population had at least one event in the category being reported? The denominator indicates how many participants were considered at risk for that category. In this record, the serious-event grouping lists 4 affected participants among 13 at risk, and the other-event grouping lists 13 affected participants among 13 at risk. These figures do not state how many total episodes occurred, because one participant may experience more than one event. The record’s primary endpoint uses participants as its unit.

Counts are useful because they preserve the scale of the observed experience. They should be interpreted in relation to the population definition, follow-up period and event definition. Here, the safety analysis set comprises participants who received at least 1 immunization, and the described monitoring period is up to 14 months. The registry record does not provide additional detail about individual follow-up duration or exposure time, so the counts should not be read as event rates per unit of time.

What uncertainty means

In general, an estimate from a study is subject to sampling uncertainty: another group of participants could have a different observed experience even under similar study conditions. A confidence interval is a range constructed by a statistical method to represent uncertainty around an estimate. It is not a guarantee that the true value lies within that particular range, and its interpretation depends on the method and assumptions used. No confidence interval for the primary safety findings is reported in the registry record.

A small sample can make estimates unstable. Each observed participant has a pronounced influence on a count when the group is small, and rare outcomes may be missed. The absence of a listed event would not establish that the event cannot occur. At the same time, an observed event is not proof that the study intervention caused it. A comparator, event attribution and detailed follow-up can help answer different questions, but this trial’s posted safety counts alone do not supply those elements.

Why the design limits comparisons

Randomized comparative studies use allocation to create groups intended to be comparable, on average, apart from the assigned intervention. This study was single-group, with allocation recorded as not applicable, so that comparative structure is absent. There is no like-for-like control group in the registry record. A before-and-after description, if available, would not automatically replace a concurrent control because other changes over time can affect outcomes. No such analysis is reported.

Open-label means the study was not masked. In general, knowledge of treatment can affect reporting, assessment or care, depending on the outcome and procedures. The registry describes laboratory tests, physical examinations and vital signs as sources for treatment-emergent adverse events, with severity graded according to NCI CTCAE, Version 4.0. The record does not report additional safeguards or adjudication procedures, so their use should not be assumed.

Multiplicity and secondary outcomes

Multiplicity arises when several outcomes or statistical tests are considered: even when each test follows its nominal error rate, the chance of at least one apparently notable finding can increase across a collection of tests. Statistical plans may address this by specifying a primary outcome, ordering tests or adjusting inference. The registry identifies a primary safety objective and secondary aims for humoral and cellular immunogenicity, tumor response, survival and time to subsequent therapy. A multiplicity strategy is not reported in the registry record. The record also reports no analyses, so it does not provide a set of inferential results on which to assess multiplicity adjustments.

How to read the planning illustrations

General sample-size planning asks how many participants may be needed to detect an effect under stated assumptions. The planning illustration associated with the posted results is described as using a two-sided significance level of 0.05, equal allocation between two arms and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. It is a planning illustration, not the trial’s own design justification, and its hypothetical two-arm allocation does not change the fact that the study itself had one group. Such planning values are not observed power and are not evidence that the study was adequately powered for a particular outcome. The trial’s sample-size justification is not reported in the registry record.

These methods distinctions help separate description from inference. The safety counts can characterize what was recorded in this group. The absence of a control group, confidence intervals and reported analyses limits how precisely the record can support claims about comparative risk or secondary outcomes.

10. Multiplicity, Missing Data and Analysis Populations

The registry record identifies safety as the primary objective and lists secondary objectives covering MAGE-A3-specific humoral and cellular immunity, tumor response, survival and time to subsequent therapy. Considering several outcomes raises a general multiplicity issue: if many statistical tests are conducted, some may appear notable by chance alone. A study may prespecify an approach to managing this issue, but a multiplicity adjustment or testing hierarchy is not reported in the registry record.

The record reports 5 outcome measures and no analyses. It therefore does not provide a set of outcome-specific estimates, tests or confidence intervals for assessing how missingness or multiplicity affected the reported findings. Details about missing observations, reasons for missingness, imputation, censoring rules and sensitivity analyses are not reported in the registry record. These details matter because incomplete follow-up can change which participants contribute to an outcome and what an estimate represents.

The safety analysis population is described as participants who received at least 1 immunization. The posted safety figures list 13 participants at risk in both the serious-event and other-event groupings. The record does not give further participant flow or explain whether any enrolled participant was excluded from a particular analysis. It also does not report how missing safety measurements, if any, were handled.

Without an analysis plan and further reporting, it is not possible to determine whether all intended analyses were conducted or how unreported outcomes were handled. These are reporting limitations, not evidence that a particular method was or was not used. The sample-size justification and any interim-analysis plan are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: psoriasis (7.7%), connective tissue disorder (7.7%), diarrhoea (7.7%), vomiting (7.7%), nausea (7.7%).

The safety record lists 4 affected participants among 13 at risk in the serious-event grouping. For the other-event grouping, it lists 13 affected among 13 at risk. These are participant counts, not counts of every individual event episode. A participant may have experienced more than one event, and the registry figures do not provide episode totals.

The serious-event terms listed are psoriasis, connective tissue disorder, diarrhoea, vomiting, nausea and injection site reaction, each at 7.7%. The term-level percentages should be read as registry-reported values; the record does not give further event-level detail or explain whether each term occurred in a different participant. No death count is reported in the registry record.

Seriousness and severity are not interchangeable concepts. The primary endpoint description says severity was graded according to NCI CTCAE, Version 4.0, but the listed term percentages do not provide a severity grade. Nor do these figures establish causation: “treatment-emergent” describes the safety assessment’s focus on events arising during the study period, not proof that the immunization produced an event.

With no comparator group, these counts describe observed safety experience rather than a difference attributable to treatment. The record does not report a comparative risk estimate or confidence interval for these figures.

12. What the Result Does, and Does Not, Mean

The main result represented by the posted safety figures is descriptive: adverse events were recorded among participants in a phase 1, single-group study of recMAGE-A3 plus AS15 around autologous stem cell transplantation. The safety set is defined as participants who received at least 1 immunization, and the monitoring period was described as up to 14 months. The figures report affected participants in serious-event and other-event groupings, together with a list of serious-event terms.

These observations do not show what would have happened to comparable participants without the study immunizations or under another treatment. Because there was no control group, the record cannot estimate a treatment-related increase or reduction in events using a randomized comparison. The event counts also do not prove that the intervention caused any listed event. A treatment-emergent event may occur during treatment or follow-up without being caused by treatment.

The record’s secondary aims included immune responses and clinical outcomes, but an objective is not the same as a reported result. The registry record reports no analyses, so the available information does not establish findings about humoral or cellular immunogenicity, tumor response, survival or time to subsequent therapy. Those outcomes should not be inferred from the safety figures.

Precision is also limited by the size and design of the study. The safety counts describe a small enrolled group, and the registry record does not report confidence intervals for the primary safety findings. A count can be informative about what was observed while still leaving substantial uncertainty about the frequency of events in a broader population.

Accordingly, the appropriate statistical reading is bounded: the record characterizes reported events in this study population under the stated monitoring approach. It does not provide a comparative treatment effect, establish event causation, or resolve the secondary clinical questions. Those conclusions would require additional reported analyses and, for comparative claims, an appropriate comparison design.

13. Why This Trial Matters Statistically

This trial illustrates how an early-phase, single-group study can contribute descriptive safety information while leaving comparative questions unanswered. The primary objective focused on safety and tolerability, an appropriate type of question to distinguish from an efficacy comparison. The registry describes a defined treatment setting, a specific immunization schedule and a safety analysis population, which gives context for understanding the observed counts.

Statistically, the distinction between participants with events and total event episodes is important. Participant counts summarize how many people experienced at least one event in a grouping, while episode counts would answer a different question. The registry’s serious-event and other-event figures are participant-based, and the listed serious-event terms are reported separately. Keeping those quantities distinct prevents the counts from being interpreted as event totals.

The design also makes clear why an observed event count is not a treatment effect. Without a control group, the data do not show how event experience compares with another course of care. This is especially important in a transplant-related setting, where the study intervention is not the only possible influence on events. The record does not provide a basis for assigning causation to the intervention.

Finally, the stated secondary objectives show why a registry’s objective list should be separated from its reported analyses. Immune responses and clinical outcomes were among the aims, but the record reports no analyses. Statistical interpretation depends not only on which questions were planned, but also on the estimates, uncertainty and methods reported for answering them. This study is therefore useful as a case in reading safety summaries cautiously and matching conclusions to the design and results actually recorded.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is the single-group design. With no concurrent comparator, observed events cannot be contrasted with an alternative treatment or control condition. The open-label design also means the study was not masked; the registry does not report additional procedures that might address possible effects of treatment knowledge on event assessment or reporting.

The enrolled sample was 13 participants, and the safety analysis set includes participants who received at least 1 immunization. Counts from this small group describe the recorded experience but provide limited information about uncommon events or event frequencies in a broader population. The registry record does not report confidence intervals for the safety counts, making their statistical precision harder to assess.

The primary safety description refers to treatment-emergent adverse events from laboratory tests, physical examinations and vital signs, with severity graded according to NCI CTCAE, Version 4.0. The registry record does not report detailed event timing, participant-level follow-up, exposure-adjusted rates, event attribution or event-level severity grades for the listed terms. The death count is not reported in the registry record.

Although secondary objectives included immune response and clinical outcomes, the registry record reports no analyses. Results for those aims, their analysis populations and their uncertainty are therefore not characterized by the posted information. Missing-data procedures, multiplicity methods, interim analyses and the trial’s sample-size justification are not reported in the registry record.

These limitations constrain interpretation rather than negate the descriptive value of the observed safety information. They mean that the record should not be used to infer comparative effects, causation or unreported secondary outcomes.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation — NCT01380145.
• Registry record last updated 2022-10-25; status last verified 2022-10.
• Results first posted 2016-12-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01380145 is a completed phase 1, open-label, single-group pilot study of recMAGE-A3 protein plus AS15 as consolidation for people with multiple myeloma undergoing autologous stem cell transplantation. The registry reports enrollment of 13 participants and a total of 8 pre- and post-transplant immunizations.

The primary objective was safety and tolerability, assessed through treatment-emergent adverse events from clinical laboratory tests, physical examinations and vital signs, with severity graded according to NCI CTCAE, Version 4.0. Monitoring was described as continuing for up to 14 months. The serious-event grouping lists 4 affected participants among 13 at risk; the other-event grouping lists 13 affected among 13 at risk. Six serious-event terms are listed at 7.7% each.

Secondary aims concerned humoral and cellular immunogenicity, tumor response, survival and time to subsequent therapy. The registry record reports no analyses. With no comparator group, the safety figures are descriptive and do not establish comparative effects or event causation.